logo-loader

Nvidia faces 2028 growth concerns as UBS cuts price target to US$220

Published: 07:15 19 Nov 2026 EST

Nvidia Corp - Nvidia faces 2028 growth concerns as UBS cuts price target to US$220

UBS has cut its price target on Nvidia Corp (NASDAQ:NVDA, XETRA:NVD), the semiconductor maker, by 8% to US$220 from US$240, while retaining its 'buy' rating.

The revised valuation reflects concerns about slowing growth in calendar 2028, despite strong near-term demand and improving revenue visibility.

UBS analyst Timothy Arcuri, alongside associate analysts Seth Cho and Gianmarco Vella, lowered its earnings forecast for calendar 2028 to US$18.80 per share from US$20.01.

The bank maintained its valuation multiple at 12 times forecast earnings, applying it to the reduced profit estimate to calculate the new target.

The revision followed Nvidia's fiscal third-quarter results, which delivered revenue of US$115.8 billion, beating UBS and market expectations by 5-6%.

Non-GAAP earnings per share reached US$2.68, above UBS's US$2.53 forecast and the market consensus of US$2.48, while gross margin was 74.9%.

Nvidia guided for fiscal fourth-quarter revenue of approximately US$130 billion, with gross margin of 71-72%, broadly matching UBS's expectations.

Learn more about Nvidia

Read more about Nvidia

The company also raised its calendar 2027 revenue growth guidance to 75% from 70%, reinforcing confidence in demand for its artificial intelligence processors.

UBS highlighted a substantial increase in supply and capacity commitments, which reached approximately US$430 billion in the latest quarter, against US$311 billion previously.

More than US$100 billion of the increase related to supply commitments for fiscal 2028, covering calendar 2027, providing further support for the company's near-term growth outlook.

However, commitments for fiscal 2029, corresponding to calendar 2028, increased only modestly, leaving questions about the potential slowdown in longer-term demand.

Arcuri also warned that Nvidia could become increasingly dependent on purchase commitments, potentially forcing it to spend more supporting customers to sustain revenue growth.

The bank pointed to a more measured approach towards supporting neocloud providers, which form an important customer base, as another development worth monitoring.

UBS also highlighted the delayed filing of Nvidia's latest quarterly 10-Q report, with management indicating that an ongoing investigation could require additional risk disclosures.

Despite these concerns, the bank expects Nvidia to remain well positioned in the near term, maintaining its positive recommendation while adjusting longer-term earnings assumptions.

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

1 hour, 48 minutes ago